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Uric acid therapy for vasculoprotection 
in acute ischemic stroke
Sergi Amaro1,2, Francesc Jiménez-Altayó3, Ángel Chamorro1,2
Abstract:
Uric acid (UA) is a product of the catabolism of purine nucleotides, the principal constituents of DNA, 
RNA, and cellular energy stores, such as adenosine triphosphate. The main properties of UA include 
scavenging of hydroxyl radicals, superoxide anion, hydrogen peroxide, and peroxynitrite that make 
this compound to be the most potent antioxidant in the human plasma. As the result of two silencing 
mutations in the gene of the hepatic enzyme uricase which degrades UA to allantoin, humans have 
higher levels of UA than most mammals. However, these levels rapidly decrease following an acute 
ischemic stroke (AIS), and this decrement has been associated to worse stroke outcomes. This 
review highlights the safety and potential clinical value of UA therapy in AIS, particularly in patients 
more exposed to redox‑mediated mechanism following the onset of ischemia, such as women, 
hyperglycemic patients, or patients treated with mechanical thrombectomy. The clinical findings are 
supported by preclinical data gathered in different laboratories, and in assorted animal species which 
include male and female individuals or animals harboring comorbidities frequently encountered in 
patients with AIS, such as hyperglycemia or hypertension. A remarkable finding in these studies is 
that UA targets its main effects in the brain vasculature since available evidence suggests that does 
not seem to cross the blood–brain barrier. Altogether, the available data with UA therapy extend the 
importance of vasculoprotection for effective neuroprotection at the bedside and reinforce the role 
of endothelial cells after brain ischemia for an increased survival of the whole neurovascular unit.
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Introduction
Despite the continuous progress made in the general care of patients with 
acute ischemic stroke (AIS) including the 
implementation of reperfusion therapies, 
up to one‑third of stroke survivors remain 
with substantial disability. Therefore, 
improved approaches including effective 
neuroprotectants are imperative to 
diminish the burden of AIS worldwide. 
Neuroprotection in AIS refers to “any 
strategy, or combination of strategies, 
that antagonizes, interrupts, or slows 
the sequence of injurious biochemical 
and molecular  events  that ,  i f  le f t 
unchecked, would eventuate in irreversible 
ischemic injury.”[1] Likewise, treatment 
approaches that primarily target the 
cerebral vasculature rather than the brain 
parenchyma are described under the term 
of vasculoprotection.[2]
Arguably, a better understanding of how 
drugs affect the different components 
of the neurovascular unit could assist in 
the design and implementation of a more 
successful clinical translation. However, a 
majority of the available studies that used 
neuroprotectant drugs did not specifically 
address neither the patency nor the 
structure of the brain microvasculature, 
which are essential components for 
effective brain reperfusion, and hence, 
successful parenchymal protection.[3] On 
the contrary, an improved knowledge of 
preclinical drugs effects before the conduct 
of clinical studies could allow the design 
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of enriched randomized clinical trials (RCTs), where 
more homogeneous treatment populations could be 
evaluated, namely, the enriched studies could facilitate 
the prospective use of any patient characteristic to 
select the best responder individuals in RCT, in which 
detection of a drug effect (if one i, in fact, present) 
is more likely than it would be in an unselected 
population. In addition, enrichment strategies could 
also allow a treatment effect to be more readily 
discerned in smaller study populations, thus reducing 
the high costs of clinical trials. In this review, we 
argue that one appealing strategy would be the 
study of neuroprotectants in patients who reperfuse 
the occluded vessel after AIS either by the use of 
thrombolytic agents or mechanical devices, as brain 
reperfusion renders the ischemic brain vulnerable to 
mechanisms otherwise less germane in patients who 
harbor permanent vessel occlusions.[4] It also highlights 
the contribution of the vasculature for the normal 
function of the whole neurovascular unit in search of 
a more successful neuroprotection in AIS.
Search Strategy
Review of the literature was conducted through Internet 
search on public access website PubMed and Medline 
databases until 2018. Keywords utilized included uric 
acid (UA), neuroprotection, vasculoprotection, and 
stroke therapy. Titles that were felt to meet criteria were 
subjected to further review.
The Ischemic Cascade
Numerous investigations on the mechanisms of the 
brain ischemic cascade have singled out the role of 
excitotoxicity, inflammation, oxidative‑nitrosative 
stress, apoptosis, and their complex bidirectional 
or multidirectional relationships.[5‑9] Excitotoxicity, 
mitochondrial dysfunction, and reactive oxygen/nitrogen 
species (ROS/RNS) production are linked processes after 
brain ischemia, as failure in energy production from 
mitochondria after the ischemic insult, leads rapidly 
to ROS/RNS production, membrane depolarization, 
removal of the voltage‑dependent Mg2+ block of the 
N‑methyl‑d‑aspartate receptor, and its subsequent 
activation leading to increased intracellular Ca2+ levels. 
The latter contributes to proteinase activation and free 
radical generation during the early ischemic phase,[10] 
and a much larger rise of these toxic compounds during 
early reperfusion, both in neurons and endothelial 
cells.[11] In agreement with the available evidence, most 
therapeutic approaches developed in the laboratory and 
translated into RCT, focused on protecting the brain from 
these stressors, although hitherto with disappointing 
results.[12] A full analysis of the reasons for the failure 
of neuroprotection in AIS is beyond the scope of this 
review,[13] but likely contributing factors would be that 
heterogeneous populations of patients were assessed 
and that few patients enrolled in the studies received 
concomitant reperfusion therapies.[14] Arguably, only 
a minority of patients reperfused after stroke in these 
studies, and in consequence, the neuroprotectants that 
were evaluated did not reach the ischemic brain or the 
vasculature or otherwise did it at inadequately low 
concentrations. Currently, these limitations could be 
overcome given the growing use of pharmacological 
and/or mechanical reperfusion therapies in patients 
with AIS, which may facilitate the design of RCT where 
all patients would require having an adequate brain 
reperfusion before testing the value of any putative new 
neuroprotectant drug.[15]
Endothelial Cells: A Cornerstone in the 
Neurovascular Unit
It is accepted that vasculogenic endothelial cells and 
nascent vessels in the developing heart, lung, pancreas, 
stomach, or gut, are critical for the earliest stages 
of organogenesis, before blood vessel function.[16] 
A similar relationship is likely to operate between 
the brain parenchyma and its circulatory system, 
and that interference of signals originated at the 
local vasculature may result in brain dysfunction. In 
the central nervous system, the vascular basement 
membrane separates the endothelial cells from 
neurons and glial cells and also contributes to vessel 
development and formation and maintenance of the 
blood–brain barrier (BBB).[17] The function of cerebral 
arteries is critical to maintain cerebrovascular resistance 
and minimize damage to ischemic brain regions 
after focal cerebral ischemia/reperfusion (I/R).[18] 
Endothelial cells are the site of the BBB and control the 
traffic of ions, molecules, and cells into and out of the 
brain.[19] Under physiological conditions, endothelial 
cells determine the thromboresistance property of 
vessels,[20] suppress pro‑inflammatory gene expression, 
the recruitment of monocytes, and the development of 
atherosclerosis.[21] Endothelial cells also affect resting 
cerebral blood flow (CBF) and mediate vasodilator 
responses to shear stress, neurotransmitters, metabolic 
factors, and therapeutic agents, and contribute to the 
normal function of neural and glial cells.[22] Effects of 
endothelial cells on the underlying smooth muscle at 
the vessel wall are major regulators of vessel tone, either 
by the release of vasoactive molecules that diffuse into 
the smooth muscle or through endothelium‑dependent 
hyperpolarization of vascular muscle.[23] Given this 
panoply of effects, endothelial dysfunction may 
represent a keystone event in the pathogenesis of 
neurovascular injury, and effective vasculoprotection 
might translate into clinically relevant therapeutic 
tactics.[24]
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Endothelial Cells and Brain Ischemia
Brain I/R impairs both basal and receptor‑mediated 
endothelium‑dependent vasodilation of large arteries, 
and parenchymal arterioles alike, despite it results 
in an increase in both endothelial nitric oxide (NO) 
synthase expression and endothelium‑derived 
hyperpolarization‑type dilations.[25,26] I/R also result in 
loss of proportional and spatially controlled changes in 
CBF elicited by neural activity (neurovascular coupling), 
and a loss of myogenic tone and autoregulation, making 
the CBF to follow passively the changes in arterial 
pressure.[27] ROS and RNS as well as vasoactive factors 
such as NO, endothelin‑1, vascular endothelial growth 
factor (VEGF), and angiopoietin I, play important roles 
in regulation of vascular tone and structure in the acute 
phase of the brain ischemia.[28] Restoring nutritive 
blood flow to the ischemic brain is essential for tissue 
survival, but reentry of oxygen and glucose into the 
ischemic region also represents a double sword that 
brings about an excess production of ROS and RNS, 
which may trigger cellular responses ranging from 
subtle modulations of cell signaling to overwhelming 
oxidative/nitrosative injury, committing cells to necrosis 
or apoptosis.[10,29‑32] Sources of high concentrations of 
ROS and RNS are the mitochondria,[33] the activity of 
cyclooxygenase enzymes,[34] nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase expressed 
by vessel wall cells (e.g., endothelial cells),[35] brain 
pericytes,[36] and infiltrating neutrophils,[37] as well 
as the hypoxic‑dependent conversion of xanthine 
dehydrogenase into xanthine oxidase (XOR).[38] Further, 
whole‑tissue homogenates of the human brain have failed 
to exhibit significant XOR activity, immunohistochemical 
studies have revealed high levels of XOR antigen in 
brain vascular endothelium. Endothelial dysfunction is 
in part attributed to the effects of superoxide anion,[39] 
which is formed when oxygen acquires an additional 
electron and can react, among others, with arachidonic 
acid forming isoprostanes, or react with NO to produce 
peroxynitrite (ONOO–). The latter is particularly toxic 
as it crosses readily biological membranes and interacts 
with most critical biomolecules.[40,41] Under experimental 
conditions, reactive species are largely generated in 
the ischemic penumbra for about 6–12 h after stroke 
onset,[42] facilitating the demise of the penumbra by 
lipid peroxidation, mitochondrial damage, protein 
nitration and oxidation, depletion of antioxidant 
reserves, activation or inhibition of various signaling 
pathways, DNA damage, and BBB breakdown.[43] Recent 
evidence suggests that ONOO– formed during I/R 
can disrupt endothelial filamentous‑actin augmenting 
endothelium‑derived hyperpolarization‑type dilations 
of cerebral arteries, a mechanism whereby ONOO– could 
contribute to promote postischemic brain injury.[26] 
Ischemia also induces sustained contraction of pericytes 
on microvessels despite successful recanalization in mice, 
and suppression of ONOO– relieves pericyte contraction, 
reduces erythrocyte entrapment, restores microvascular 
patency, and improves the tissue survival. [44] 
Interestingly, by comparing the ROS‑suppressing effect 
of  N‑tert ‑butyl‑α ‑phenylnitrone (PBN) with 
i ts  BBB impermeable  analog 2‑sulfophenyl‑ 
N‑tert‑butylnitrone (S‑PBN) in mice, Taskiran‑Sag et al. 
found that PBN and S‑PBN completely suppressed 
the reperfusion‑induced increase in ROS signal within 
vasculature;[45] PBN readily suppressed ROS produced 
in parenchyma and S‑PBN suppressed the parenchymal 
ROS sometimes later. Yet, both compounds comparably 
reduced the size of the ischemic area and S‑PBN 
restored the microvascular patency and perfusion after 
recanalization, suggesting that its delayed parenchymal 
antioxidant effect could be secondary to improved 
microcirculatory reperfusion.[45]
After ischemia, the BBB loses parts of its barrier properties, 
driving endothelial cell induction of selectins and 
integrins, and secretion of pro‑inflammatory compounds 
such as tumor necrosis factor‑α, interleukin‑1 (IL‑1) β, IL‑6, 
monocyte chemoattractant protein‑1, cytokine‑induced 
neutrophil chemoattractant, and prostaglandins.[46,47] 
These events primarily affect postcapillary venules, 
where leukocytes adhere to swollen endothelium 
and infiltrate the brain parenchyma across the BBB.[48] 
Neutrophils have a remarkable destructive potential, 
either through the direct neurotoxic effects from the 
release of proteolytic enzymes[49,50] or through indirect 
effects that result from intravascular neutrophil 
accumulation, capillary blood flow obstruction, 
the no‑reflow phenomenon,[51] or activation of the 
complement system.[52] Neutrophils can also extravasate 
from the leptomeningeal vessels and reach the brain 
in experimental animal models and human studies of 
permanent arterial occlusion.[53] Finally, a vicious cycle 
of inflammatory activation on both endothelial cells 
and leukocytes may contribute to increased vascular 
permeability and vasogenic edema.[54]
Uric Acid: A Potent Extracellular 
Antioxidant
UA is a product of the catabolism of purine nucleotides, 
the principal constituents of DNA, RNA, and cellular 
energy stores, such as adenosine triphosphate. In most 
mammals, UA is rapidly degraded by the hepatic 
enzyme uricase (urate oxidase) to allantoin,[55] but 
in humans, the uricase gene is nonfunctional. As a 
consequence, humans have higher UA levels than most 
mammals, in concentration almost tenfold higher than 
other antioxidants that contribute up to 60% of the total 
plasma antioxidant activity in healthy controls.[56] The 
main properties of UA include scavenging of hydroxyl 
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radicals, superoxide anion, hydrogen peroxide, and 
peroxynitrite; suppression of the Fenton reaction; 
chelation of transition metals; and prevention of lipid 
peroxidation.[57]
Uric Acid Therapy Following Brain 
Ischemia: Preclinical Data
Accumulating data attest the beneficial role of UA to 
minimize the negative consequences of the ischemic 
cascade. Yu et al. first described the dose‑dependent 
effects of UA therapy to prevent cell death induced 
by exposure to glutamate and cyanide in cultured 
rat hippocampal neurons and showed that UA was 
neuroprotective administered following I/R in rats.[58] 
Romanos et al. identified the synergistic effects of UA 
and recombinant tissue plasminogen activator (rtPA) 
in a model of thromboembolic brain ischemia in rats.[59] 
In mice, Haberman et al. showed improved outcome, 
smaller infarcts, and reduced ROS production with UA 
therapy following I/R or permanent middle cerebral 
artery (MCA) occlusion,[60] and Ma et al. confirmed 
smaller infarcts, improved behavior, and reduced 
superoxide anion production and nitrotyrosination in 
brain, following I/R.[61] Preclinical studies have also 
demonstrated improved stroke outcomes following UA 
therapy in hyperglycemic mice,[62] female mice,[63] and in 
female rats.[64]
Uric Acid Mainly Targets the Vasculature
Onetti et al. showed in male rats that UA therapy 
attenuated the MCA wall thickening following I/R, 
and induced passive lumen expansion, reduced brain 
damage, and reduced nitrotyrosination in both the 
MCA and the brain tissue.[65] UA treatment prevented 
the increased wall and adventitial volume, and the 
augmented number of adventitial cells, but not smooth 
muscle cells. Remarkably, all these effects were more 
significant in animals with hyperemia after I/R.[66] 
A decrease in the myogenic response occurs during 
ischemia and is considered an important factor involved 
in the functional dysregulation of CBF after I/R.[66] 
However, UA treatment during reperfusion did not 
restore the myogenic response. Further, quantitative 
analysis of mRNA levels of NADPH oxidase (major 
source of vascular superoxide anion) subunits showed 
augmented mRNA expression in hyperemic animals, and 
this effect in conjunction with the enhanced oxidative 
stress was attenuated by UA.[65]
UA therapy after I/R in normotensive rats also exerted 
long‑term brain protective effects which were associated 
with attenuation of the short‑term rise in both circulating 
levels of IL‑18 and cerebrovascular oxidative stress.[67] 
Strikingly, UA treatment attenuated both short‑ and 
long‑term brain damage in hypertensive rats, an effect 
associated with abolishment of the acute oxidative stress 
response and prevention of stroke‑induced long‑lasting 
MCA remodeling. Further, in BBB permeability assays, 
the permeability of UA was poor, suggesting that it 
did not cross the BBB by passive transport. Indeed, UA 
plasma levels increased 10 min after intravenous (IV) 
UA administration, whereas UA levels in brain tissue 
were unaffected by UA infusion, suggesting that the 
main protective target of this compound was the brain 
vasculature.[67]
Beneficial actions of UA following I/R have been 
associated with the activation of the Nrf2 transcription 
factor and regulation of neurotrophic factor expression.[68] 
Our group further showed in spontaneously hypertensive 
rats that UA treatment induced Kruppel‑like factor 
2 (KLF2) expression, and lowered VEGF‑A levels 
while reduced BBB leakage, and improved endothelial 
cell barrier integrity.[69] KLF2 is a transcription factor 
that modulates essential cellular functions, including 
regulation of endothelial cell growth, differentiation 
and activation,[70] and protects mice from thrombus 
formation by a decreased expression of endothelial 
thrombotic factors.[71] Human VEGF‑A is a Janus‑faced 
molecule, since together with its proangiogenic and 
neuroprotective effects, it disrupts the BBB integrity, 
leading to edema, hemorrhage, and brain damage.[72] 
Previously, it was shown that UA inhibits angiogenesis 
of cultured endothelial cells through KLF2‑induced 
negative regulation of VEGF‑A expression.[73] Altogether, 
these findings strongly support the concepts that UA 
is primarily a vasculoprotective compound and that 
this effect may be ultimately responsible for the overall 
neuroprotection and improved outcome shown in 
experimental studies.
Uric Acid Therapy Following Brain 
Ischemia: Clinical Data
The beneficial effects of UA found in preclinical 
models have also a promising translation into the 
clinic. In particular, Chamorro et al. first described 
in patients with AIS that higher endogenous levels 
of UA at clinical onset were associated with better 
stroke outcome.[74] Reassuringly, this finding was later 
confirmed in a meta‑analysis of 8131 patients with 
AIS.[75] Waring et al. showed that IV administration of 
UA was safe in healthy volunteers, increased serum 
free‑radical scavenging capacity at rest and during acute 
physical exercise, and abolished lipid peroxidation.[76] We 
conducted a pilot study that showed the safety of IV UA 
administration in 24 patients with AIS treated with rtPA 
treated within 3 h of clinical onset,[77] established in 44 h 
the half elimination life of the compound and found that 
UA treated patients had lower increments of activated 
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metalloproteinase‑9 at follow‑up.[78] Importantly, this 
pilot study also described a rapid consumption of 
the circulating levels of endogenous UA in untreated 
patients.[77]
The Phase 2 URICO‑ICTUS trial confirmed the safety 
of a single 90‑min infusion of 1 g UA administration 
in 421 patients with AIS treated with rtPA within 
4.5 h of symptom onset.[79] The trial showed an overall 
nonsignificant 6% absolute increment in the rate of 
good outcome at follow‑up but showed a highly 
significant reduction in the incidence of early stroke 
worsening stroke in treated patients.[80] Preplanned 
analyses in subgroups of patients more vulnerable 
to oxidative/nitrosative stress, demonstrated highly 
significant effects of UA therapy in the primary outcome 
of URICO‑ICTUS (modified Rankin Scale score at day 
90). These important subgroups included women,[81] 
hyperglycemic patients,[82] and patients treated with 
mechanical thrombectomy (MT).[83] A greater benefit 
of UA therapy in females could be attributed to lower 
endogenous levels of UA in this sex group and therefore 
greater exposure than males to unopposed toxic‑free 
radicals.[81] The greater benefit of UA therapy observed 
in hyperglycemic patients accord with preclinical 
studies establishing that glucose exacerbates ischemic 
brain injury because it is the main electron donor for 
reperfusion‑induced neuronal superoxide production 
in AIS.[84] Indeed, inactivation of neuronal superoxide 
production in mice counterbalances the deleterious 
effects of hyperglycemia after brain ischemia.[84] Finally, 
the greater benefit of UA therapy versus placebo in the 
subpopulation of patients treated with MT, which has 
the greatest brain reperfusion rate, is justified by the 
abundant experimental evidence indicating a much 
higher production of ROS and RNS, whenever brain 
reperfusion occurs. Confirmation of these provocative 
findings is planned in a pivotal RCT of patients treated 
with MT.
Conclusions
This review highlights the safety and potential 
clinical value of UA therapy in AIS, particularly in 
patients more exposed to deleterious redox‑mediated 
mechanisms following ischemic brain damage, such 
as females, patients with moderate increase of glucose 
levels at stroke onset, or patients treated with MT. 
This assumption is supported by preclinical data 
gathered in different laboratories, assorted species, 
and male and female animals harboring comorbidities 
that frequently affects patients with AIS, such as 
hyperglycemia or hypertension. Altogether, the 
available data with UA therapy extend the importance 
of vasculoprotection for effective neuroprotection at 
the bedside and reinforce the role of endothelial cells 
after brain ischemia for an increased survival of the 
whole neurovascular unit.
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